3/3
11:42 pm
alxo
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update [Yahoo! Finance]
Medium
Report
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update [Yahoo! Finance]
3/1
09:26 am
alxo
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]
Medium
Report
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]
2/28
09:03 am
alxo
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
06:12 pm
alxo
ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [Seeking Alpha]
Low
Report
ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [Seeking Alpha]
2/27
04:34 pm
alxo
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... [Yahoo! Finance]
Low
Report
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... [Yahoo! Finance]
2/27
08:28 am
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/27
08:00 am
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2/19
08:53 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 [Yahoo! Finance]
High
Report
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 [Yahoo! Finance]
2/19
08:53 am
alxo
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 [Yahoo! Finance]
High
Report
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 [Yahoo! Finance]
2/19
08:33 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
High
Report
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
2/19
08:30 am
alxo
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
High
Report
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
2/9
11:32 am
alxo
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
2/5
07:18 am
alxo
ALX Oncology (NASDAQ:ALXO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
ALX Oncology (NASDAQ:ALXO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/31
03:52 pm
alxo
ALX Oncology Announces Pricing of Underwritten Offering [Yahoo! Finance]
Low
Report
ALX Oncology Announces Pricing of Underwritten Offering [Yahoo! Finance]
1/30
08:32 am
alxo
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer [Yahoo! Finance]
Medium
Report
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer [Yahoo! Finance]
1/30
08:30 am
alxo
ALX Oncology Announces Pricing of Underwritten Offering
High
Report
ALX Oncology Announces Pricing of Underwritten Offering
1/30
08:15 am
alxo
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
High
Report
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
1/15
05:21 pm
alxo
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
Low
Report
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
1/12
01:16 pm
alxo
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
Neutral
Report
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
1/8
11:00 am
alxo
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/8
08:30 am
alxo
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
Medium
Report
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
12/22
01:07 am
alxo
12/14
01:27 am
alxo
Medium
Report
12/7
08:00 am
alxo
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Low
Report
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting